Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Intense exercise is a major challenge to the management of type 1 diabetes (T1D). Closed-loop control (CLC) systems (artificial pancreas) improve glycemic control during limited intensity and short duration of physical activity (PA). However, CLC has not been tested during extended vigorous outdoor exercise common among adolescents. RESEARCH DESIGN AND METHODS: Skiing presents unique metabolic challenges: intense prolonged PA, cold, altitude, and stress/fear/excitement. In a randomized controlled trial, 32 adolescents with T1D (ages 10–16 years) participated in a 5-day ski camp (∼5 h skiing/day) at two sites: Wintergreen, VA, and Breckenridge, CO. Participants were randomized to the University of Virginia CLC system or remotely monitored sensor-augmented pump (RM-SAP). The CLC and RM-SAP groups were coarsely paired by age and hemoglobin A1c (HbA1c). All subjects were remotely monitored 24 h per day by the study physicians and clinical team. RESULTS: Compared with physician-monitored open loop, percent time in range (70–180 mg/dL) improved using CLC: 71.3 vs. 64.7% (+6.6% [95% CI 1–12]; P = 0.005), with maximum effect late at night. Hypoglycemia exposure and carbohydrate treatments were improved overall (P = 0.001 and P = 0.007) and during the daytime with strong ski level effects (P = 0.0001 and P = 0.006); ski/snowboard proficiency was balanced between groups but with a very strong site effect: naive in Virginia and experienced in Colorado. There was no adverse event associated with CLC; the participants’ feedback was overwhelmingly positive. CONCLUSIONS: CLC in adolescents with T1D improved glycemic control and reduced exposure to hypoglycemia during prolonged intensive winter sport activities, despite the added challenges of cold and altitude.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and (3) the first”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [128]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Automated insulin delivery systems can potentially modify insulin dosing in response to activity monitors to reduce the risk (or severity) of exercise-induced hypoglycemia in people living with type 1 diabetes [7-10].”
From Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study (2018) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602
Weinzimer, S. A., Steil, G. M., Swan, K. L., Dziura, J., Kurtz, N., & Tamborlane, W. V. (2008) · Diabetes Care · doi:10.2337/dc07-1967 · Cited by 567
Hovorka, R., Allen, J. M., Elleri, D., Chassin, L. J., Harris, J., Xing, D., Kollman, C., Hovorka, T., Larsen, A. M. F., Nodale, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61998-x · Cited by 450 · cited 2×
“control while decreasing the rates of hyperglycemia and hypoglycemia in inpatient trials (5,10,11), at diabetes camps”
BackgroundMethodHome Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip, M., Battelino, T., Atlas, E., Kordonouri, O., Bratina, N., Miller, S., Biester, T., Avbelj Stefanija, M., Muller, I., Nimri, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206881 · Cited by 435 · cited 1×
“There have also been several older studies investigating the role of overnight glucose control with AP in a camp setting (13,26) that confirmed the trend of re-”
BackgroundClosed-Loop Artificial Pancreas Systems: Engineering the Algorithms
Doyle, F. J., Huyett, L. M., Lee, J. B., Zisser, H. C., & Dassau, E. (2014) · Diabetes Care · doi:10.2337/dc13-2108 · Cited by 394 · cited 1×
“CLC systems involve the pairing of a continuous subcutaneous insulin infusion pump and a continuous glucose monitor (CGM) with a CLC algorithm that automatically adjusts insulin infusion in real time (4).”
BackgroundComing of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223 · cited 2×
“Reviews and collections of papers reflecting the progress of the AP field are published regularly (2,3).”
BackgroundOutcome measures for artificial pancreas clinical trials: a consensus report
Maahs, D. M., Buckingham, B. A., Castle, J. R., Cinar, A., Damiano, E. R., Dassau, E., DeVries, J. H., Doyle, F. J., Griffen, S. C., Haidar, A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2716 · Cited by 211 · cited 1×
“Primary outcome was the percent time spent between 70 and 180 mg/dL (22), with secondary outcomes focusing on the quality of glycemic control, including percent time spent between 70 and 140 mg/dL, average CGM, and total insulin used.”
BackgroundSelf-citation
Cited by
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
Self-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Moser, O., Riddell, M. C., Eckstein, M. L., Adolfsson, P., Rabasa-Lhoret, R., van den Boom, L., Gillard, P., Nørgaard, K., Oliver, N. S., Zaharieva, D. P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05263-9 · Cited by 214
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
Self-citationSafety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 Diabetes
Forlenza, G. P., Pinhas-Hamiel, O., Liljenquist, D. R., Shulman, D. I., Bailey, T. S., Bode, B. W., Wood, M. A., Buckingham, B. A., Kaiserman, K. B., Shin, J., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0264 · Cited by 182
Self-citationRiddell, M. C., Li, Z., Gal, R. L., Calhoun, P. M., Jacobs, P. G., Clements, M. A., Martin, C. K., Doyle, F. J., Patton, S. R., Castle, J. R., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1721 · Cited by 196
“Continuous moderate-intensity aerobic exercise is known to promote a decline in glycemia in type 1 diabetes (14), even if HCL systems are used (15,16).”
BackgroundReddy, R. K., Pooni, R., Zaharieva, D. P., Senf, B., El Youssef, J., Dassau, E., Doyle III, F. J., Clements, M. A., Rickels, M. R., Patton, S. R., et al. (2018) · JMIR mHealth and uHealth · doi:10.2196/10338 · Cited by 155
“Although some studies have shown the limitation of these devices as compared with the gold standard ECG measure of HR [24,28], these chest-based HR monitors have been used to inform glucose control systems of exercise [8,10,15].”
Castle, J. R., El Youssef, J., Wilson, L. M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., Leitschuh, J., Rajhbeharrysingh, U., Senf, B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0228 · Cited by 152
“(22) described the use of a model-based single-hormone system in adolescents skiing/snowboarding.”
BackgroundIoMT-Enabled Real-Time Blood Glucose Prediction With Deep Learning and Edge Computing
Zhu, T., Kuang, L., Daniels, J., Herrero, P., Li, K., & Georgiou, P. (2022) · IEEE Internet of Things Journal · doi:10.1109/jiot.2022.3143375 · Cited by 184
“Similar IoMT-enabled AP systems with cloud services have been reported in the literature, such as the Bionic pancreas [48] and DiAs system [49].”
MethodForlenza, G. P., Ekhlaspour, L., Breton, M., Maahs, D. M., Wadwa, R. P., DeBoer, M., Messer, L. H., Town, M., Pinnata, J., Kruse, G., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0011 · Cited by 109
Self-citationIs an artificial pancreas (closed‐loop system) for Type 1 diabetes effective?
Boughton, C. K., & Hovorka, R. (2018) · Diabetic Medicine · doi:10.1111/dme.13816 · Cited by 118
Sherr, J. L., Buckingham, B. A., Forlenza, G. P., Galderisi, A., Ekhlaspour, L., Wadwa, R. P., Carria, L., Hsu, L., Berget, C., Peyser, T. A., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0286 · Cited by 92
Self-citationMoser, O., Riddell, M. C., Eckstein, M. L., Adolfsson, P., Rabasa‐Lhoret, R., Boom, L., Gillard, P., Nørgaard, K., Oliver, N. S., Zaharieva, D. P., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13105 · Cited by 91
Forlenza, G. P., Cameron, F. M., Ly, T. T., Lam, D. W.-H., Howsmon, D. P., Baysal, N., Kulina, G., Messer, L. H., Clinton, P. K., Levister, C. M., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0424 · Cited by 94
Self-citationKarageorgiou, V., Papaioannou, T., Bellos, I., Alexandraki, K., Tentolouris, N., Stefanadis, C., Chrousos, G. P., & Tousoulis, D. (2018) · Metabolism · doi:10.1016/j.metabol.2018.10.002 · Cited by 95
“21, I(2)=37%) after the exclusion of 5 studies [32,37,38,41,43].”
BackgroundEvolution of Diabetes Technology
Dovč, K., & Battelino, T. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.009 · Cited by 132
Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy
Fuchs, J., & Hovorka, R. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1784724 · Cited by 104
First Look at Control-IQ: A New-Generation Automated Insulin Delivery System
Brown, S. A., Raghinaru, D., Emory, E. G., & Kovatchev, B. P. (2018) · Diabetes Care · doi:10.2337/dc18-1249 · Cited by 90
“, Europe, Israel, and Argentina, which ensured external validity of the data (2,3,5,7,8,13,14).”
BackgroundSelf-citationMoser, O., Zaharieva, D. P., Adolfsson, P., Battelino, T., Bracken, R. M., Buckingham, B. A., Danne, T., Davis, E. A., Dovč, K., Forlenza, G. P., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06308-z · Cited by 111
Self-citationAutomated closed-loop control of diabetes: the artificial pancreas
Kovatchev, B. P. (2018) · Bioelectronic Medicine · doi:10.1186/s42234-018-0015-6 · Cited by 91
Self-citationA Century of Diabetes Technology: Signals, Models, and Artificial Pancreas Control
Kovatchev, B. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.04.008 · Cited by 80
Self-citationEkhlaspour, L., Forlenza, G. P., Chernavvsky, D., Maahs, D. M., Wadwa, R. P., Deboer, M. D., Messer, L. H., Town, M., Pinnata, J., Kruse, G., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12867 · Cited by 76
Self-citationZaharieva, D. P., Messer, L. H., Paldus, B., O'Neal, D. N., Maahs, D. M., & Riddell, M. C. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.06.003 · Cited by 84
Self-citationJoseph, J. I. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820911919 · Cited by 81
Petruželková, L., Šoupal, J., Plasova, V., Jiranova, P., Neuman, V., Plachý, L., Průhová, Š., Šumník, Z., & Obermannová, B. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0214 · Cited by 78
Reddy, N., Verma, N., & Dungan, K. M. (2020) · MDText.com, Inc. eBooks · Cited by 108
Multivariable Artificial Pancreas for Various Exercise Types and Intensities
Turksoy, K., Hajizadeh, I., Hobbs, N., Kilkus, J. M., Littlejohn, E., Samadi, S., Feng, J., Sevil, M., Lazaro, C., Ritthaler, J., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0072 · Cited by 75
Time in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
Randomized Controlled Trial of Mobile Closed-Loop Control
Kovatchev, B., Anderson, S. M., Raghinaru, D., Kudva, Y. C., Laffel, L. M., Levy, C., Pinsker, J. E., Wadwa, R. P., Buckingham, B., Doyle, F. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1310 · Cited by 60
“Subsequently, DiAs was used in a number of studies by.300 participants at 10 clinical centers in the U.S. and Europe (8,9), including longterm trials at home (10) and the first “stress test” of a CLC systemdthe Artificial Pancreas Ski Trial, where children with type 1 diabetes used DiAs during 5- day winter sport camp…”
BackgroundSelf-citationEckstein, M. L., Weilguni, B., Tauschmann, M., Zimmer, R. T., Aziz, F., Sourij, H., & Moser, O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112445 · Cited by 66
“duration of the physical exercise period [34,35].”
BackgroundMethodInfluentialTagougui, S., Taleb, N., & RABASA-LHORET, R. P. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00818 · Cited by 64
Wilson, L. M., Jacobs, P. G., Ramsey, K., Resalat, N., Reddy, R. K. K., Branigan, D. L., LEITSCHUH, J. A., Gabo, V. B., Guillot, F. H., Senf, B., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2267 · Cited by 64
Koufakis, T., Karras, S. Ν., Mustafa, O. G., Zebekakis, P. E., & Kotsa, K. (2018) · High Altitude Medicine & Biology · doi:10.1089/ham.2018.0076 · Cited by 60
“A different study included 32 adolescents (10–16 years of age) with T1D treated with closed-loop control (CLC) systems (artificial pancreas), who participated in a 5-day ski camp, up to a maximum altitude of 3963 m in Breckenridge, Colorado (Breton et al., 2017).”
A New Blood Glucose Control Scheme for Unannounced Exercise in Type 1 Diabetic Subjects
Beneyto, A., Bertachi, A. H., Bondía, J., & Vehí, J. (2018) · IEEE Transactions on Control Systems Technology · doi:10.1109/tcst.2018.2878205 · Cited by 63
“Insulin-only AP systems have been widely tested in response to exercise; see [5]–[7] for other recent studies.”
ResultGarcia-Tirado, J., Diaz, J. L., Esquivel-Zuniga, R., Koravi, C. L. K., Corbett, J. P., Dawson, M., Wakeman, C., Barnett, C. L., Oliveri, M. C., Myers, H., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0932 · Cited by 52
Self-citationRiddell, M. C., Li, Z., Beck, R. W., Gal, R. L., Jacobs, P. G., Castle, J. R., Gillingham, M. B., Clements, M. A., Patton, S. R., Dassau, E., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0495 · Cited by 59
Adaptive personalized multivariable artificial pancreas using plasma insulin estimates
Hajizadeh, I., Rashid, M. M., Samadi, S., Sevil, M., Hobbs, N., Brandt, R., & Çınar, A. (2019) · Journal of Process Control · doi:10.1016/j.jprocont.2019.05.003 · Cited by 56
Barriers to Uptake of Insulin Technologies and Novel Solutions
PAULEY, M. E., Berget, C., Messer, L. H., & Forlenza, G. P. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s312858 · Cited by 73
“Our own group has studied HCL technology during winter sports and demonstrated the safety of these systems during extremes of temperature, altitude, and exercise, even among young children.(118,119) Dermatological issues are a noted barrier to device use.”
BackgroundSelf-citationPaldus, B., Morrison, D., Zaharieva, D. P., Lee, M. H., Jones, H., Obeyesekere, V. R., Lu, J., Vogrin, S., Gerche, A. L., McAuley, S. A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1593 · Cited by 56
The year of transition from research to clinical practice
Kovatchev, B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.170 · Cited by 48
Self-citationKovatchev, B. P., Kollar, L. L., Anderson, S. M., Barnett, C. L., Breton, M. D., Carr, K., Gildersleeve, R., Oliveri, M. C., WAKEMAN, C. A., & Brown, S. A. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30218-3 · Cited by 50
“Eligibility: T1D for at least 1 year, using an insulin pump for at least six months, ages 18 years or older.”
BackgroundInfluentialSelf-citationRiddell, M. C., Gal, R. L., Bergford, S., Patton, S. R., Clements, M. A., Calhoun, P. M., Beaulieu, L. C., & Sherr, J. L. (2023) · Diabetes Care · doi:10.2337/dc23-1548 · Cited by 48
Garcia‐Tirado, J., Brown, S. A., Laichuthai, N., Colmegna, P. H., Koravi, C. L. K., Özaslan, B., Corbett, J. P., Barnett, C. L., Pajewski, M., Oliveri, M. C., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0516 · Cited by 53
Self-citationTagougui, S., Taleb, N., Molvau, J., Nguyen, É., Raffray, M., & RABASA-LHORET, R. P. R. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819869310 · Cited by 57
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Self-citationClosed-loop insulin delivery: update on the state of the field and emerging technologies
Ware, J., & Hovorka, R. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2142556 · Cited by 47
Michou, P., Gkiourtzis, Ν., Christoforidis, A., Kotanidou, E. P., & Galli-Tsinopoulou, A. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110678 · Cited by 51
Hanaire, H. P., Franc, S., Borot, S., Penfornis, A., Benhamou, P., Schaepelynck, P., Renard, É., Guerci, B., Jeandidier, N., Simon, C., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13898 · Cited by 46
Riddell, M. C., Pooni, R., Yavelberg, L., Li, Z., Kollman, C., Brown, R. E., Li, A., & Aronson, R. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.003 · Cited by 48
Tagougui, S., Taleb, N., Legault, L., Suppère, C., Messier, V., Boukabous, I., Shohoudi, A., Ladouceur, M., & Rabasa-Lhoret, R. (2020) · Diabetologia · doi:10.1007/s00125-020-05244-y · Cited by 40
Forlenza, G. P., Buckingham, B. A., Christiansen, M. P., Wadwa, R. P., Peyser, T. A., Lee, J. B., OCONNOR, J. B., Dassau, E., Huyett, L. M., Layne, J. E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0017 · Cited by 41
Self-citationJacobs, P. G., Resalat, N., Hilts, W. W., Young, G. M., LEITSCHUH, J. A., Pinsonault, J., Youssef, J. E., Branigan, D. L., Gabo, V. B., Eom, J. H., et al. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00112-7 · Cited by 52
“29 Control-IQ and other commercial AIDs do not use physical activity as an input.”
Visser, H. S. D., Waraich, S., Chhabra, M., Yamamoto, J. M., Zenlea, I. S., Askin, N., Rabbani, R., McGavock, J., TEAM Trial Patient Coresearchers, Greenberg, D. T., et al. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.2740 · Cited by 43
Improving Glucose Prediction Accuracy in Physically Active Adolescents With Type 1 Diabetes
Hobbs, N., Hajizadeh, I., Rashid, M. M., Turksoy, K., Breton, M. D., & Çınar, A. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818820550 · Cited by 38
Self-citationArtificial Pancreas: Clinical Study in Latin America Without Premeal Insulin Boluses
Sánchez‐Peña, R., Colmegna, P. H., Garelli, F., Battista, H. D., García-Violini, D., Moscoso-Vásquez, M., Rosales, N., Fushimi, E., Campos-Náñez, E., Breton, M. D., et al. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818786488 · Cited by 41
“Although AP systems have shown improved glycemic control in T1DM, glucose regulation during postprandial and exercise periods remains a challenge.(7-9) It has been essential for gaining momentum in designing and testing glucose controllers, the development of elaborated simulators, such as the Universities of Virginia…”
BackgroundSelf-citationSchoelwer, M. J., Robic, J. L., Gautier, T., Fabris, C., Carr, K., Oliveri, M. C., Brown, S. A., Anderson, S. M., DeBoer, M. D., Cherñavvsky, D. R., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0471 · Cited by 34
Self-citationBenhamou, P., Huneker, E., Franc, S., Doron, M., & Charpentier, G. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1123-1 · Cited by 32
Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes
Dadlani, V., Pinsker, J. E., Dassau, E., & Kudva, Y. C. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1051-z · Cited by 32
Asgharzadeh, A., Patel, M., Connock, M. J., Damery, S. L., Ghosh, I., Jordan, M., Freeman, K., Brown, A., Court, R. A., Baldwin, S., et al. (2024) · Health Technology Assessment · doi:10.3310/jypl3536 · Cited by 37
Riddle, M. C., Gerstein, H. C., & Cefalu, W. T. (2017) · Diabetes Care · doi:10.2337/dci17-0049 · Cited by 30
“(4) report experimental use of a closed-loop system during vigorous exercise by a small group of young people with T1D, with encouraging results.”
BackgroundPaldus, B., Morrison, D., Lee, M., Zaharieva, D. P., Riddell, M. C., & O'Neal, D. N. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088327 · Cited by 37
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement
Scott, S. N., Fontana, F. Y., Cocks, M. S., Morton, J. P., Jeukendrup, A. E., Dragulin, R., Wojtaszewski, J. F. P., Jensen, J., Castol, R., Riddell, M. C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00054-1 · Cited by 37
Moser, O., Eckstein, M. L., Mueller, A., Birnbaumer, P., Aberer, F., Koehler, G., Sourij, C., Kojzar, H., Holler, P., Simi, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13534 · Cited by 28
“The median (interquartile range) amount of accompanying physical exercise, as documented by the participants, was also not significantly different between the two dosing schemes: 100% IDeg: 30 (8-54) min/wk versus 75% IDeg: 20 (3-35) min/wk (P = 0.”
BackgroundInfluentialKang, S. L., Hwang, Y. N., Kwon, J. Y., & Kim, S. M. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00962-2 · Cited by 32
“2 [29] 2017 32 t:AP pump or Roche Accu-Chek Spirit Combo pump,”
BackgroundThe International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability
Anderson, S. M., Dassau, E., Raghinaru, D., Lum, J. W., Brown, S. A., Pinsker, J. E., Church, M. M., Levy, C. J., Lam, D. W.-H., Kudva, Y. C., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0308 · Cited by 26
Self-citationGarcia‐Tirado, J., Colmegna, P. H., Corbett, J. P., Özaslan, B., & Breton, M. D. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819879084 · Cited by 24
Self-citationA clinical review of the t:slim X2 insulin pump
Berget, C., Lange, S. L., Messer, L. H., & Forlenza, G. P. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1814734 · Cited by 27
Self-citationThe closed‐loop artificial pancreas in 2020
Fabris, C., & Kovatchev, B. P. (2020) · Artificial Organs · doi:10.1111/aor.13704 · Cited by 24
Self-citationClosed-loop insulin delivery: current status of diabetes technologies and future prospects
Majeed, W., & Thabit, H. (2018) · Expert Review of Medical Devices · doi:10.1080/17434440.2018.1503530 · Cited by 27
Weight Management in Youth with Type 1 Diabetes and Obesity: Challenges and Possible Solutions
Zaharieva, D. P., Addala, A., Simmons, K. M., & Maahs, D. M. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00411-z · Cited by 21
Self-citationElbarbary, N. S., & Ismail, E. A. R. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01184-w · Cited by 20
Viñals, C., Beneyto, A., José, J., Furió-Novejarque, C., Bertachi, A. H., Bondía, J., Vehí, J., Conget, I., & Giménez, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa562 · Cited by 26
Colmegna, P. H., Bianchi, F. D., & Sánchez‐Peña, R. (2020) · IEEE Control Systems Letters · doi:10.1109/lcsys.2020.3041211 · Cited by 25
“Previous AP strategies that address this problem can be found in [8]–[13] and a recent survey, in [14].”
BackgroundBraune, K., May, A., & Thurm, U. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819884922 · Cited by 17
Diabetes Technology and Exercise
Riddell, M. C., Pooni, R., Fontana, F. Y., & Scott, S. N. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.011 · Cited by 19
Diabetes Technology: Monitoring, Analytics, and Optimal Control
Kovatchev, B. P. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034389 · Cited by 17
“5) (Breton et al. 2017).”
Self-citationMesser, L. H., Berget, C., Ernst, A., Towers, L., Slover, R. H., & Forlenza, G. P. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13183 · Cited by 16
“satisfaction [10 (9, 10)], high convenience [10 (9, 10)], and high usefulness [10 (9, 10)] of the check-in call.”
BackgroundInfluentialSelf-citationHerrero, P., El-Sharkawy, M., Daniels, J., Jugnee, N., Uduku, C. N., Reddy, M., Oliver, N. S., & Georgiou, P. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819881456 · Cited by 17
“There is already clinical evidence that by announcing exercise, an AP can better cope with such perturbation by reducing the exercise-induced hypoglycemia.(20) Another possible solution to address this challenge is the incorporation of glucagon delivery as counter-regulatory action to insulin in a dual-hormone AP.”
BackgroundEsefeld, K., Kreß, S., Behrens, M., Zimmer, P., Stümvoll, M., Thurm, U., Gehr, B., Brinkmann, C. K., & Halle, M. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1284-6097 · Cited by 20
Wildevuur, S. E., Simonse, L. W. L., Groenewegen, P., & Klink, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025930 · Cited by 16
“20 21 Most of the studies are about developing AP systems that would still require user entry of carbohydrate intake (hybrid closed -loop systems).”
Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes
Dovč, K., & Battelino, T. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1713747 · Cited by 15
“Two outpatient studies tested closed-loop insulin therapy during prolonged and intensive winter sport activities involving youth with type 1 diabetes [66,67].”
BackgroundSaydah, S., Imperatore, G., Divers, J., Bell, R. A., Henkin, L. F., Mayer‐Davis, E. J., Zhong, V. W., Dabelea, D., Lawrence, J. M., & Pihoker, C. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.57 · Cited by 12
Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems
Dovč, K., Battelino, T., Beck, R. W., Sibayan, J., Bailey, R. J., Calhoun, P. M., Turcotte, C., WEINZIMER, S. A., Schweiger, D. Š., Nimri, R., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0153 · Cited by 12
How Well Do Continuous Glucose Monitoring Systems Perform During Exercise?
Castle, J. R., & Rodbard, D. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0132 · Cited by 12
Mise en place de l’insulinothérapie automatisée en boucle fermée : position d’experts français
Franc, S., Schaepelynck, P., Tubiana‐Rufi, N., Chaillous, L., Joubert, M., Renard, É., Reznik, Y., Abettan, C., Bismuth, É., Beltrand, J., et al. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(20)30003-1 · Cited by 24
Zimmer, R. T., Birnbaumer, P., Sternad, C., Zunner, B. E. M., Schierbauer, J., Fritsch, M., Fröhlich-Reiterer, E. E., Hofmann, P., Sourij, H., Aberer, F., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15352 · Cited by 14
“TIRs of 63.2% (CL) and 62.8% (CSII) for 330 minutes, 46 and of 57.8% (CL) and 55.9% (CSII) for 240 minutes, 47 for moderate-intensity skiing, were recorded.”
InfluentialTechnology in Diabetes Treatment: Update and Future
Schiel, R., Bambauer, R., & Steveling, A. (2018) · Artificial Organs · doi:10.1111/aor.13296 · Cited by 14
Chakrabarty, A., Zavitsanou, S., Sowrirajan, T., Doyle, F. J., & Dassau, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00011-9 · Cited by 11
Where Do We Stand with Closed-Loop Systems and Their Challenges?
Jackson, M. A., & Castle, J. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0469 · Cited by 13
Artificial pancreas systems: experiences from concept to commercialisation
Rodríguez-Sarmiento, D. L., Vargas, F. M. L., & Maira, G. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2150546 · Cited by 11
Molveau, J., RABASA-LHORET, R. P. R., Myette‐Côté, É., Messier, V., Suppère, C., Potter, K. J., Heyman, E., & Tagougui, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.953879 · Cited by 11
Morrow, D., Kirk, A. F., Muirhead, F., & Lennon, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19106315 · Cited by 14
Moser, O., Zaharieva, D. P., Adolfsson, P., Battelino, T., Bracken, R. M., Buckingham, B. A., Danne, T., Davis, E. A., Dovč, K., Forlenza, G. P., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000542287 · Cited by 15
Self-citationAutomated Insulin Delivery in Children with Type 1 Diabetes.
Cengiz, E. (2020) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2019.10.012 · Cited by 7
Wilderness Medical Society Clinical Practice Guidelines for Diabetes Management
VanBaak, K., Nally, L. M., Finigan, R. T., Jurkiewicz, C., Burnier, A., Conrad, B., Khodaee, M., & Lipman, G. S. (2019) · Wilderness and Environmental Medicine · doi:10.1016/j.wem.2019.10.003 · Cited by 9
Diabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., & Shalitin, S. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.2509 · Cited by 8
Self-citationSperling, M. A., Wolfsdorf, J. I., Menon, R. K., Tamborlane, W. V., Maahs, D. M., Battelino, T., & Phillip, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00021-x · Cited by 13
Self-citationAjčević, M., Candido, R., Assaloni, R., Accardo, A., & Francescato, M. P. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820945372 · Cited by 8
Metadata
- Authors
- Breton, M. D., Cherñavvsky, D. R., Forlenza, G. P., DeBoer, M. D., Robic, J., Wadwa, R. P., Messer, L. H., Kovatchev, B. P., & Maahs, D. M.
- Affiliations
- University of Virginia (US)
- University of Colorado Denver (US)
- Corresponding author
- Breton, Marc D.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-08-30
- Volume
- 40
- Issue
- 12
- Pages
- 1644-1650
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5711335
- OpenAlex
- W2752733073
- Cited by
- 179
- References
- 31
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 11 · 2023: 18 · 2022: 10 · 2021: 17 · 2020: 36 · 2019: 31 · 2018: 28 · 2017: 3
- FWCI
- 21.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH-DP3-DK106826)
- University of Colorado Foundation
- Children’s Diabetes Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, feedback control, artificial pancreas, adolescents, prolonged exercise, skiing, glycemic control, hypoglycemia, time in range, sensor-augmented pump, cold exposure, altitude, winter sports
- MeSH terms
- Adolescent, Blood Glucose, Child, Cold Temperature, Colorado, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Humans, Hypoglycemia, Seasons, Skiing, Virginia, Blood Glucose Self-Monitoring, Exercise, Body Mass Index, Treatment Outcome, Pancreas, Artificial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.